摘要
目的探讨高血压病患者ACE基因I/D多态性与卡托普利咳嗽副反应、ACE水平的关系。方法筛选高血压病患者,检测ACE基因I/D多态性,按ACEI/D基因型分为II型、ID型和DD型三组,给予卡托普利降压治疗8周,随访观察患者咳嗽副反应发生情况,紫外法检测治疗前后ACE水平。比较三组间上述指标的差异,并分析其间的可能关系。结果ACEII组咳嗽副反应发生率(57.1%),显著高于ID组(P<0.05)、DD组(P<0.05);ID组咳嗽副反应发生率较DD组为高,但差异无统计学意义(P>0.05)。三组间治疗前、治疗后ACE水平差异有显著统计学意义(P均<0.001);治疗前DD组显著高于ID组(P<0.001)、II组(P<0.001),ID组显著高于II组(P<0.001);治疗后结果相同(P均<0.001)。结论携带ACEII基因型的高血压病患者服用卡托普利,咳嗽副反应的发生率高于其它两型患者,ACE水平低于其他两型患者,ACE水平较低是高血压病患者出现ACEI相关性咳嗽的重要原因。
Objective To investigate whether the I/D polymorphism of angiotensin converting enzyme （ACE） gene is associated with the incidence of captepril induced cough and the level of ACE. Methods The ACE genotypes were detected in patients with hypertension and were classified as DD, Ⅱ and ID groups. All the patients have taken catopril for 8 weeks and were followed up to observe the incidence of induced cough. ACE was determined by ultraviolet spectrometry before and after treatment. The indices mentioned above were compared among the three groups, and the possible, correlation among them was analyzed. Results The incidence of induced cough in ACE Ⅱ genotype group was 57.1%, which was significantly higher than that in groups of ID （P〈 0.05） and DD genotypes （P〈 0.05）. The incidence of induced cough in ID genotype group was higher than that of DD genotype group, but no significant difference was found （P 〉0.05）. There were significant differences in the level of ACE before and after treatment among the three groups （all P〈 0. 001）. Before treatment, the level of ACE in DD genotype group was significantly higher than that in groups of ID（P〈 0.001）and Ⅱ genotypes （P〈 0.001）, and the level of ACE in ID genotype group was significantly higher than that in Ⅱ genotype group （P〈 0. 001）. After treatment, the results were similar to those before treatment （all P〈0.001）. Conclusion The patients of AOE Ⅱ genotype have a lower level of ACE and a higher incidence of induced cough after taking captopril Low level of ACE is a key factor in the ACEI related cough in patients with hypertension.
出处
《实用预防医学》
CAS
2009年第2期327-330,共4页
Practical Preventive Medicine
基金
重大基础研究前期研究专项(2005CCA04000)
中央保健专项资金科研课题(169)资助
